Regenerative Therapies for Gut Health and Healing

Regenerative Therapies for Gut Health: BPC-157, Leaky Gut, and Integrative Chiropractic Care

Abstract

Can regenerative therapies help improve gut health? Emerging research suggests that regenerative medicine may eventually offer new ways to support the repair of damaged intestinal tissue, restore the mucosal lining, regulate inflammation, and improve the environment in which intestinal stem cells function. Researchers are studying stem cells, organoids, microbiome-based treatments, immune therapies, and specialized peptides for these purposes.

One peptide receiving attention is BPC-157, or Body Protection Compound-157. Laboratory and animal studies suggest that BPC-157 may support cytoprotection, blood vessel formation, epithelial repair, and control of excessive inflammation. These effects have created interest in BPC-157 for increased intestinal permeability, commonly called “leaky gut.” However, most evidence for BPC-157 remains preclinical, human research is limited, and BPC-157 is not currently an FDA-approved drug.

At Injury Medical Clinic PA in El Paso, Texas, a multidisciplinary model combines the clinical perspectives of Dr. Alexander Jimenez, DC, APRN, FNP-BC, CCST, CFMP, IFMCP, ATN, and Dr. Maria Guadalupe Cardenas, MD, a physician with more than 40 years of internal medicine experience. This approach brings together medical oversight, integrative chiropractic care, functional medicine, rehabilitation, personal injury care, and other appropriate services while keeping experimental regenerative treatments within proper medical and regulatory boundaries.

Can Regenerative Medicine Help the Gut Heal?

The short answer is possibly, but much of the science is still developing.

The intestinal lining is not a passive wall. It is an active layer of cells that helps:

• Absorb nutrients.
• Keep harmful substances out of the bloodstream.
• Communicate with the immune system.
• Interact with trillions of microorganisms.
• Replace damaged intestinal cells.
• Regulate inflammation.

The intestinal epithelium normally renews itself rapidly. Intestinal stem cells help produce the new cells needed to maintain this barrier. Research funded by the California Institute for Regenerative Medicine has explored stem cells and stem-cell-derived intestinal organoids as possible ways to restore damaged epithelial tissue in inflammatory bowel disease (California Institute for Regenerative Medicine [CIRM], n.d.).

This does not mean stem-cell therapy is currently a routine treatment for “leaky gut.” It means scientists are learning how regenerative biology may eventually help restore injured intestinal tissue.

The Gut Lining Is a Regenerative Organ

Every day, the digestive tract faces stomach acid, digestive enzymes, food particles, bacteria, medications, alcohol, inflammatory chemicals, and mechanical stress.

Fortunately, the intestine has its own repair system.

Intestinal stem cells continuously produce new epithelial cells. Newer research also shows that the gut microbiome may influence how well these stem cells work.

A 2026 report from the International Society for Stem Cell Research described animal research showing that age-related changes in gut bacteria reduced intestinal stem-cell activity. When researchers restored a more youthful microbial environment in older mice, intestinal stem-cell activity and tissue regeneration improved (International Society for Stem Cell Research [ISSCR], 2026).

Other research has found that metabolites produced by gut bacteria may stimulate intestinal stem cells and strengthen the intestinal barrier after major medical treatments such as radiation and stem-cell transplantation (Leibniz Institute for Immunotherapy, 2025).

Together, these findings suggest that regeneration, the microbiome, immune function, and the intestinal barrier are closely connected.

What Is “Leaky Gut”?

The term leaky gut is commonly used to describe increased intestinal permeability.

Normally, cells lining the intestine form a carefully controlled barrier. Tight junctions between these cells help determine what passes through the intestinal wall.

When this barrier is injured, or its regulation changes, substances from the intestinal contents may cross the barrier more easily.

Possible contributors include:

• Intestinal inflammation.
• Certain infections.
• Alcohol exposure.
• Some medications, including NSAIDs.
• Changes in gut bacteria.
• Poor nutrition.
• Chronic gastrointestinal disease.
• Severe illness or medical treatment.

Increased permeability has been studied in inflammatory and gastrointestinal disorders, but “leaky gut syndrome” should not be treated as a stand-alone diagnosis without determining why the intestinal barrier may be abnormal.

This is where a proper medical evaluation becomes important.

BPC-157: A Gastric-Protective Peptide Undergoing Research

BPC-157 is a synthetic peptide made from a sequence of 15 amino acids related to compounds studied in gastric tissues.

The peptide has attracted attention because preclinical research suggests that it may influence several healing pathways.

These include:

• Cytoprotection: helping cells tolerate injury.
• Angiogenesis: supporting formation of new blood vessels.
• Fibroblast activity: helping cells involved in repair.
• Collagen production: supporting tissue structure.
• Nitric oxide signaling: influencing blood vessels and tissue protection.
• Inflammatory signaling: potentially controlling excessive inflammatory activity.
• Epithelial healing: supporting repair of surface tissues.

A 2020 review by Park et al. examined experimental evidence suggesting that BPC-157 could protect gastrointestinal tissues from NSAID-related injury and stabilize intestinal permeability. The authors discussed BPC-157 as a possible cytoprotective compound for gastrointestinal injury, but much of the evidence came from experimental models rather than large human clinical trials (Park et al., 2020).

A broader 2026 review also reported that animal studies have shown BPC-157 activity involving gastrointestinal healing, angiogenesis, collagen production, cell migration, and inflammatory pathways. Importantly, the authors stressed that human data remain very limited and that many proposed benefits are not yet clinically proven (Yuan et al., 2026).

How Might BPC-157 Affect the Intestinal Epithelium?

Think of the intestinal lining like a tightly connected tile floor.

If the tiles become damaged and the connections between them weaken, the barrier becomes less effective.

Experimental BPC-157 research suggests several possible ways the peptide could influence this repair process.

Supporting epithelial cell repair

Experimental studies have associated BPC-157 with pathways involved in cell migration and tissue rebuilding.

Supporting blood flow

Healing tissue needs oxygen and nutrients. BPC-157 appears to influence VEGF-related signaling and blood-vessel development in preclinical models (Yuan et al., 2026).

Modulating inflammation

A damaged intestinal barrier can activate immune responses. Experimental studies suggest BPC-157 may influence inflammatory cytokines rather than functioning simply as a traditional anti-inflammatory medication.

Protecting the gastrointestinal lining

Animal studies have reported protective effects in the stomach, esophagus, small intestine, and other gastrointestinal tissues.

These findings help explain why BPC-157 is being investigated for intestinal permeability. They do not, however, establish that BPC-157 is a proven treatment for human leaky gut, Crohn’s disease, ulcerative colitis, IBS, ulcers, or other gastrointestinal diseases.

Patient-education sources discussing BPC-157 appropriately describe the peptide as promising but unproven, since large controlled human studies are still lacking (Ubie Health, n.d.; Tucson Wellness MD, n.d.).

Regenerative Medicine Goes Beyond BPC-157

BPC-157 is only one small part of the larger regenerative-medicine field.

Researchers are investigating several ways to help damaged digestive tissue repair itself.

Intestinal stem cells and organoids

Scientists can grow miniature intestinal structures called organoids from stem cells. These models allow researchers to study epithelial repair and may one day contribute to treatments designed to replace severely damaged intestinal tissue (CIRM, n.d.).

Microbiome-based regeneration

The microbiome produces metabolites that interact with immune cells and intestinal stem cells. Williams et al. (2023) described the microbiome as a possible regenerative medicine target because microbial changes can affect inflammatory, metabolic, immune, and neurological pathways throughout the body.

Cellular therapies

Mesenchymal stromal or stem cells are being studied for their ability to influence inflammatory signaling, immune regulation, blood-vessel growth, and tissue repair. Research into disorders such as gastroparesis remains experimental, and commercial descriptions should not be mistaken for proof of effectiveness (Stemwell, 2025).

Emerging immune-based regeneration

Researchers have even used CAR T-cell technology experimentally to remove aging cells that interfere with intestinal regeneration. In mice, the approach improved epithelial healing, nutrient absorption, and inflammation. Early laboratory findings in human intestinal cells were also encouraging, but this remains research rather than routine gastrointestinal treatment (Cold Spring Harbor Laboratory, 2026).

Could Better Gut Integrity Reduce Whole-Body Inflammation?

Possibly.

The gut interacts continuously with the immune system. When the intestinal barrier, microbiome, and immune response become disturbed, inflammatory signaling may extend beyond the digestive tract.

Gut dysbiosis has been associated with inflammatory and autoimmune conditions, and diets high in processed foods and added sugars may contribute to microbiome changes and systemic inflammation (Williams et al., 2023).

This creates an important goal for integrative care: do not focus only on a peptide.

A broader program may examine:

• Food quality and dietary patterns.
• Protein and micronutrient intake.
• Fiber tolerance.
• Hydration.
• Sleep.
• Stress.
• Medication use.
• Metabolic health.
• Physical activity.
• Gastrointestinal disease.
• Infection or dysbiosis when clinically appropriate.

The goal is to improve the environment in which normal tissue repair takes place.

Where Integrative Chiropractic Care Fits

Chiropractic treatment should not be described as directly sealing intestinal tight junctions or curing intestinal disease.

Its role is different.

Dr. Alex Jimenez’s published clinical observations emphasize combining the biological side of healing with the mechanical side of recovery. Regenerative strategies may address tissue biology, while chiropractic care and rehabilitation focus on mobility, joint mechanics, posture, strength, and movement patterns (Jimenez, 2026a, 2026b).

For someone experiencing both musculoskeletal problems and gastrointestinal concerns, integrative chiropractic care may therefore be one part of a broader plan that includes:

• Improving spinal and joint mobility.
• Reducing musculoskeletal limitations to physical activity.
• Correcting movement problems after injury.
• Progressive rehabilitation and exercise.
• Nutritional and functional medicine evaluation.
• Medical review of medications and chronic disease.
• Appropriate laboratory testing.
• Gastroenterology referral when needed.
• Monitoring for warning signs requiring conventional medical treatment.

Dr. Jimenez describes this multidisciplinary approach as treating the patient from more than one clinical angle rather than expecting one treatment to solve every problem.

Medical Oversight: Dr. Maria Guadalupe Cardenas and Dr. Alex Jimenez

At Injury Medical Clinic PA in El Paso, Texas, Dr. Maria Guadalupe Cardenas, MD, works alongside Dr. Alexander Jimenez, DC, APRN, FNP-BC, CCST, CFMP, IFMCP, ATN.

Dr. Cardenas has more than 40 years of medical experience and practices in internal medicine. Clinic materials identify her as the Medical Director and Collaborative Physician, while Dr. Jimenez serves in integrative chiropractic, advanced-practice nursing, functional medicine, injury care, and rehabilitation.

This type of multidisciplinary arrangement can provide several layers of care:

• Internal medicine oversight: medical diagnosis, medication review, risk assessment, chronic-disease management, and referral.
• Integrative chiropractic care: spinal and joint evaluation, mobility, biomechanics, and musculoskeletal treatment.
• Functional medicine: investigation of nutrition, metabolism, lifestyle factors, and possible contributors to inflammation.
• Personal injury care: evaluation and documentation of injuries after automobile, workplace, or other traumatic events.
• Rehabilitation: progressive movement, strengthening, stability, and return to activity.
• Regenerative-care review: careful consideration of emerging treatments based on evidence, regulation, medical need, and patient safety.

This teamwork is especially important when patients are asking about experimental treatments.

Important BPC-157 Safety and FDA Information

BPC-157 needs to be discussed carefully.

As of August 2026, BPC-157 is not an FDA-approved medication.

In July 2026, the FDA’s Pharmacy Compounding Advisory Committee voted to recommend BPC-157-related substances for possible inclusion on the Section 503A Bulks List. However, that vote was advisory, and it did not constitute final FDA approval or prove that BPC-157 is safe or effective for treating intestinal disease.

FDA scientific reviewers also concluded that there was insufficient clinical information to characterize BPC-157’s safety profile. FDA noted a lack of adequate human studies using proposed oral, subcutaneous, nasal, and transdermal routes and raised concerns about immunogenicity and peptide-related impurities.

Therefore:

• BPC-157 should not be advertised as a proven cure for leaky gut.
• Patients should not purchase injectable research peptides from unknown internet sources.
• Human dosing and long-term safety remain uncertain.
• Serious gastrointestinal symptoms require proper medical evaluation.
• Patients should not abandon FDA-approved treatments in favor of experimental peptides without appropriate medical guidance.

The Future of Regenerative Gut Care

The science of intestinal regeneration is advancing quickly.

Researchers are learning that the intestinal barrier depends on far more than one drug or peptide. Stem cells, epithelial cells, blood vessels, immune pathways, the microbiome, nutrition, metabolism, and lifestyle all interact.

BPC-157 is interesting because experimental research suggests cytoprotective, regenerative, vascular, and anti-inflammatory effects. But its most convincing evidence remains laboratory and animal research.

The safest message today is therefore:

BPC-157 may represent a future tool for intestinal repair, but it remains an investigational therapy rather than an established treatment for leaky gut or gastrointestinal disease.

A comprehensive approach combines sound medical diagnosis, evidence-based treatment, nutrition, functional health strategies, movement, rehabilitation, and appropriate specialty care. At Injury Medical Clinic PA, the collaboration between Dr. Jimenez and Dr. Cardenas reflects this broader philosophy: combining medical oversight with integrative chiropractic and rehabilitative care while allowing emerging regenerative science to develop through careful research rather than unsupported promises.

---

References

California Institute for Regenerative Medicine. (n.d.). Stem cell therapy for inflammatory bowel disease.

Cold Spring Harbor Laboratory. (2026, January 3). Scientists found a way to help aging guts heal themselves. ScienceDaily.

International Society for Stem Cell Research. (2026, January 22). New study shows gut microbiota directly regulates intestinal stem cell aging.

Jimenez, A. (2026a). Regenerative medicine and integrative chiropractic approaches.

Jimenez, A. (2026b). Regenerative therapies for fitness and recovery insights.

Jimenez, A. (n.d.). Dr. Alex Jimenez—Clinical and integrative health information.

Leibniz Institute for Immunotherapy. (2025, October 28). Protecting the gut after stem cell transplantation: New evidence for the potential of microbiome-based therapies.

Park, J. M., Lee, H. J., Sikiric, P., & Hahm, K. B. (2020). BPC 157 rescued NSAID-cytotoxicity via stabilizing intestinal permeability and enhancing cytoprotection. Current Pharmaceutical Design, 26(25), 2971–2981.

Ruggeri, C. (2026, January 26). What are peptides? Peptide benefits for skin and more. Dr. Axe.

Stemwell. (2025, August 15). Healing gastroparesis with stem cells: A new path to digestive health.

U.S. Food and Drug Administration. (2026). Certain bulk drug substances for use in compounding that may present significant safety risks.

U.S. Food and Drug Administration. (2026, July). Pharmacy Compounding Advisory Committee meeting: BPC-157-related bulk drug substances.

Ubie Health. (n.d.). Gut won’t heal? BPC-157 medical guide.

Williams, K. L., Enslow, R., Suresh, S., Beaton, C., Hodge, M., & Brooks, A. E. (2023). Using the microbiome as a regenerative medicine strategy for autoimmune diseases. Biomedicines, 11(6), 1582.

Yoo Direct Health. (2026). FDA peptide update: What the recent BPC-157, KPV, and TB-500 news means.

Yoo Direct Health. (n.d.). Best peptides for gut health: BPC-157, KPV, larazotide and more.

Yuan, C., Demers, A., Silva-Ortiz, V., Hasoon, J. J., Lee, W., Dave, K., Amirdelfan, K., Burke, H. W., Christo, P. J., & Robinson, C. L. (2026). From regeneration to analgesia: The role of BPC-157 in tissue repair and pain management. International Journal of Molecular Sciences, 27(6), 2876.